Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Antidepressants lessen risk of heart attack


The use of antidepressants in patients who have suffered a heart attack appears to reduce the risk of recurrent events and cardiac death, according to a large, multi-center study conducted by the National Heart, Lung and Blood Institute. The findings suggest that post-heart attack patients who suffer from depression should talk with their physicians about taking the medication.

"Our study provides much stronger evidence than we’ve ever had before that antidepressants are safe and may benefit these patients," said C. Barr Taylor, MD, professor of psychiatry and behavioral sciences at the Stanford University School of Medicine and lead author of the paper published in the July issue of Archives of General Psychiatry.

Cardiovascular disease, the leading cause of death, major morbidity and disability in the United States, is often linked with depression: according to past studies, 20 percent of patients with coronary heart disease suffer from major depression and 20 percent from minor depression. Studies have also shown that depression among post-heart attack patients is associated with death and recurrent heart attacks.

Researchers launched the ENRICHD (ENhancing Recovery In Coronary Heart Disease) study to determine whether cognitive behavioral therapy would impact mortality and morbidity in post-heart attack patients with depression. Following publication of their findings that cognitive therapy significantly reduced depression but had little effect on mortality rates, the researchers conducted a secondary analysis on the use of antidepressants among the study participants.

"Our initial results were published in JAMA, and there was some evidence that the participants on antidepressants had decreased morbidity and mortality," said Taylor. "Once we saw the effect we wanted to examine it more thoroughly."

The ENRICHD study, which is the largest psychotherapy trial in coronary patients to date, involved 1,834 depressed or "socially isolated" post-heart attack patients (985 men and 849 women). The participants were enrolled during a three-year period (October 1996-October 1999) and randomized to the therapy group or the control group.

Patients who received therapy participated in a series of individual and group sessions delivered over six to nine months. Those patients who had more severe depression or who didn’t respond after five weeks of treatment were also given sertraline hydrochloride (Zoloft). If antidepressants were still needed at the end of the study, patients were referred to physicians for subsequent treatment.

Taylor and his colleagues at eight study sites used patient interviews and records, hospital records and/or participants’ physicians to conduct follow-up evaluations six months after randomization and annually after that. By the end of the follow-up, 28 percent of the participants who had received therapy had used antidepressants, and 20 percent of participants in the control group had. The median duration of antidepressant use was 12 months for both groups, and participants were most likely to take selective serotonin reuptake inhibitors, or SSRIs, such as Zoloft instead of tricyclics or other types.

After analyzing the data, the researchers found that 26 percent of study participants who hadn’t received antidepressants died or had a recurrent heart attack, while 21 percent of those participants who had taken antidepressants at some point died or had a recurrent event. After adjusting for baseline depression and cardiac risk, SSRI use was associated with 43 percent lower risk of death or recurrent non-fatal heart attack, and 43 percent lower risk of death from all causes.

"The results basically suggest that these medications are very useful for patients who have had heart attacks and are depressed," said Taylor, adding that he would recommend that any post heart-attack patient with depression be evaluated for treatment.

While encouraged by the results, Taylor pointed out that the study does have limitations. Because the study was not designed to evaluate the use of antidepressants, its findings are observational. The researchers also lacked a direct measure of when exactly patients took the antidepressants.

The authors noted that the results of the study show a need for a prospective, randomized trial on the safety and benefit of antidepressants in this population.

Taylor is also now analyzing results of a related study, called IMPROVE (IMProve mood/Reduce risk Of Vascular Events), which examined the relationship between depression and cardiovascular physiology, risk factors and biological variables. The study focused on people who are more depressed than those in the ENRICHD study and who have not had a previous cardiovascular event.

Michelle Brandt | EurekAlert!
Further information:

More articles from Health and Medicine:

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

nachricht Researchers identify key step in viral replication
13.03.2018 | University of Pittsburgh Schools of the Health Sciences

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

Im Focus: Locomotion control with photopigments

Researchers from Göttingen University discover additional function of opsins

Animal photoreceptors capture light with photopigments. Researchers from the University of Göttingen have now discovered that these photopigments fulfill an...

Im Focus: Surveying the Arctic: Tracking down carbon particles

Researchers embark on aerial campaign over Northeast Greenland

On 15 March, the AWI research aeroplane Polar 5 will depart for Greenland. Concentrating on the furthest northeast region of the island, an international team...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

New 4-D printer could reshape the world we live in

21.03.2018 | Life Sciences

Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

21.03.2018 | Trade Fair News

Physicists made crystal lattice from polaritons

20.03.2018 | Physics and Astronomy

Science & Research
Overview of more VideoLinks >>>